Ablation of nerve endings in the right atrium for treating atrial fibrillation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of ablating nerve endings in the right atrium to treat patients with atrial fibrillation (AF) who have not responded to standard left atrial ablation. The research team has previously shown that targeting ganglionated plexuses in the left atrium can reduce AF symptoms with less heart injury. Participants will be recruited from those on the waiting list for AF ablation and will undergo a procedure to assess the impact of right atrial ganglionated plexus ablation. The study aims to provide a new treatment option for patients suffering from persistent AF.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males or females from 18 to 85yrs old
* Symptomatic paroxysmal atrial fibrillation
* Suitable candidate for catheter ablation
* Signed informed consent

Exclusion Criteria:

* Contraindication to catheter ablation
* Contraindication for general anaesthetic
* Presence of a left ventricular thrombus
* Valvular disease that is grade moderate or greater
* Any form of cardiomyopathy
* Severe cerebrovascular disease
* Active gastrointestinal bleeding
* Serum Creatinine \>200umol/L/ on dialysis/ at risk of dialysis
* Active infection or fever
* Life expectancy shorter than the duration of the trial
* Allergy to contrast
* Moderate to severe heart failure and/or NYHA Class III-IV
* Bleeding or clotting disorders or inability to receive heparin
* Uncontrolled diabetes (HbA1c ≥73mmol/mol or HbA1c ≤64mmol/mol and Fasting Blood Glucose ≥9.2mmol/L)
* Malignancy needing therapy
* Pregnancy or women of childbearing potential not using a highly effective method of contraception
* Unable to give informed consent

Where it's running

• Hammersmith Hospital
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Prapa Kanagaratnam, MBBChir, PhD — Imperial College London
• Study coordinator: Jamie Kay, MBBS BMedSci
• Email: jamie.kay@imperial.ac.uk
• Phone: 02033131000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ablation of focal activation in atrial fibrillation

  This study is testing a new method to find specific electrical signals that may be causing ongoing atrial fibrillation in patients, to see if targeting these signals can improve their treatment.

  Recruiting Imperial College London · London · NCT06402617

• Using Colchicine to Prevent Atrial Fibrillation Recurrence After Heart Rhythm Restoration

  This study is testing if a low-dose Colchicine treatment can help prevent Atrial Fibrillation from coming back in people who have just had their heart rhythm restored.

  Recruiting at 8 sites Phase 3 University Hospital, Basel, Switzerland · Bruderholz, Basel-Landschaft and 7 other locations · NCT05890664

• Evaluating new technologies for successful atrial fibrillation ablation

  This study is testing how well a common heart procedure called catheter ablation works for people with atrial fibrillation over a year to see if it helps keep their heart rhythm steady.

  Recruiting Azienda Ospedaliero, Universitaria Pisana · Pisa · NCT05617456

• AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

  This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

  Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

• Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

  This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857044

• Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation

  This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.

  Recruiting at 4 sites Biosense Webster, Inc. · Beijing and 3 other locations · NCT07845682

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.